<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Maintenance immunosuppressive therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Maintenance immunosuppressive therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Maintenance immunosuppressive therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Hardinger, PharmD, BCPS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane C Tan, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deirdre Sawinski, MD, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3086322039"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Maintenance immunosuppressive therapy is administered to almost all kidney transplant recipients to help prevent acute rejection and the loss of the kidney allograft. Although chronic baseline immunosuppression is required to dampen the immune response to the allograft, the level of chronic immunosuppression is decreased over time (as the risk of acute rejection decreases) to help lower the cumulative risk of infection and malignancy; these risks directly correlate with the degree of overall immunosuppression.</p><p>The regimens and agents used for maintenance immunosuppression following kidney transplantation will be reviewed in this topic. Other aspects of immunosuppressive therapy in kidney transplant recipients, including the treatment of rejection, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p></p><p class="headingAnchor" id="H739286804"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Practically all kidney transplant recipients require immunosuppressive therapy to prevent rejection and loss of the allograft. Most patients undergoing kidney transplantation receive induction therapy with T cell-depleting or interleukin (IL) 2 receptor–blocking antibodies at the time of kidney transplantation (see  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a>). This is followed by maintenance immunosuppression therapy, which is initiated during the hospital stay and continued for the life of the allograft.</p><p>Maintenance regimens consist of a combination of immunosuppressive agents that differ by mechanism of action  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). This strategy minimizes morbidity and mortality associated with each class of agent while maximizing overall effectiveness. Specific regimens may vary by patient, transplant center, and geographic area. The major immunosuppressive agents that are available include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) (see <a class="local">'Glucocorticoids'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcineurin inhibitors (CNIs; <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) (see <a class="local">'Calcineurin inhibitors'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimetabolite agents (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [MMF], enteric-coated mycophenolate sodium [EC-MPS], <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) (see <a class="local">'Antimetabolites'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanistic (mammalian) target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) (see <a class="local">'mTOR inhibitors'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Costimulatory blockade agents (<a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>) (see <a class="local">'Belatacept'</a> below)</p><p></p><p>For most patients, the maintenance regimen consists of a CNI (usually <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite (usually <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>), and a glucocorticoid. (See <a class="local">'Approach to maintenance therapy'</a> below.)</p><p>Some patients may require modification of the initial maintenance regimen due to the development of posttransplant complications (eg, toxicity, allograft failure, acute rejection, infection, cancer) or other clinical events (eg, pregnancy, surgery). (See <a class="local">'When and how to modify therapy'</a> below.)</p><p class="headingAnchor" id="H3741038109"><span class="h1">APPROACH TO MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>For most kidney transplant recipients, we suggest a maintenance regimen consisting of triple immunosuppression therapy with the following agents:</p><p class="bulletIndent1"><span class="glyph">●</span>A calcineurin inhibitor (CNI; usually <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) (see <a class="local">'Calcineurin inhibitors'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An antimetabolite (usually <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>) (see <a class="local">'Antimetabolites'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A glucocorticoid (usually <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) (see <a class="local">'Glucocorticoids'</a> below)</p><p></p><p>Maintenance immunosuppression is continued for the life of the allograft. An exception to this approach is in recipients of human leukocyte antigen (HLA)-identical allografts from a monozygotic twin; such patients can be treated with low-dose immunosuppression for one to three months prior to discontinuation [<a href="#rid1">1</a>]. Theoretically, no immune response would be present, because the allograft and recipient are immunologically identical [<a href="#rid1">1-4</a>].</p><p>Our approach is largely consistent with the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for kidney transplantation and the consensus recommendations for use of maintenance immunosuppression in solid organ transplantation from the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation [<a href="#rid5">5,6</a>]. Evidence supporting this approach is provided by several randomized controlled trials and meta-analyses that demonstrate &gt;90 percent allograft survival at one year and acute rejection rates of &lt;20 percent with triple immunosuppressive therapy consisting of a CNI, an antimetabolite, and a glucocorticoid [<a href="#rid7">7-10</a>].</p><p>Alternative maintenance regimens include regimens containing a mechanistic (mammalian) target of rapamycin (mTOR) inhibitor or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> in combination with an antimetabolite and a glucocorticoid, as well as glucocorticoid-free regimens (eg, dual therapy with a CNI plus an antimetabolite). However, we do <strong>not</strong> routinely use such regimens as initial maintenance immunosuppression for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of mTOR inhibitors is generally avoided in the early posttransplant period due to their association with delayed wound healing, wound dehiscence, lymphoceles, and prolonged graft dysfunction [<a href="#rid6">6</a>]. In addition, rates of acute rejection are higher with mTOR inhibitor-based regimens compared with CNI-based regimens [<a href="#rid9">9</a>]. However, an mTOR inhibitor can be used as an alternative agent in patients who cannot continue taking a CNI due to toxicity or who develop a new cancer after transplantation. (See <a class="local">'mTOR inhibitors'</a> below and <a class="local">'Calcineurin inhibitor-related toxicity'</a> below and <a class="local">'Patients with a new cancer'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">Belatacept</a>, when used as initial maintenance therapy, has been associated with higher rates of acute rejection compared with CNI-based regimens. In addition, belatacept is expensive and must be administered intravenously. However, belatacept can be used as an alternative agent in patients who cannot continue taking a CNI due to toxicity or who are nonadherent with therapy due to pill burden. A few centers have used belatacept with a time-limited course of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> as part of an initial maintenance regimen to avoid long-term use of CNIs and their associated adverse effects [<a href="#rid11">11,12</a>]; however, more data are needed. (See <a class="local">'Belatacept'</a> below and <a class="local">'Calcineurin inhibitor-related toxicity'</a> below and <a class="local">'Patients with nonadherence to therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While most (approximately two-thirds) kidney transplant recipients are maintained on long-term glucocorticoids [<a href="#rid13">13</a>], some centers use glucocorticoid-free regimens in patients at low to moderate immunologic risk [<a href="#rid5">5,6</a>]. In such patients, glucocorticoids are administered at the time of transplantation but are typically discontinued within the first few days after transplant. This is based upon the desire to minimize long-term glucocorticoid exposure, thereby decreasing the risk of adverse effects with this agent. While studies comparing early glucocorticoid withdrawal (also called glucocorticoid avoidance) with glucocorticoid continuation after kidney transplantation have shown similar long-term patient and allograft survival [<a href="#rid14">14,15</a>], rates of biopsy-proven acute rejection are higher with early glucocorticoid withdrawal [<a href="#rid15">15</a>]. Thus, we, and most centers, continue low-dose glucocorticoid therapy in all patients, regardless of risk for acute rejection. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="headingAnchor" id="H2453586691"><span class="h1">AGENTS USED FOR MAINTENANCE THERAPY</span></p><p class="headingAnchor" id="H1919294834"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are nonspecific antiinflammatory agents that interrupt multiple steps in immune activation, including antigen presentation, cytokine production, and lymphocyte proliferation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Glucocorticoid regimens vary among transplant centers, and there is no consensus on the optimal dose or maintenance schedule following kidney transplantation [<a href="#rid5">5</a>]. In the absence of acute rejection, there is little utility in maintaining patients on large doses of glucocorticoids or in tapering glucocorticoids over prolonged periods of time. Most centers attempt to taper glucocorticoids to approximately 0.05 to 0.1 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or even less) by the first few months after transplantation. At our center, patients receive intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> at the time of transplantation, followed by a rapid taper of oral prednisone to a dose of 5 mg/day by one month following kidney transplantation  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). Overall, the benefit of maintenance low-dose glucocorticoids at the doses utilized may include improved immunosuppression, modulation of calcineurin inhibitor (CNI) nephrotoxicity, reduced risk of cytopenias, and/or ability to avoid CNI use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration </strong>– The use of long-term glucocorticoids as part of a maintenance immunosuppressive regimen varies among transplant centers. We, and most centers, continue maintenance glucocorticoids indefinitely in kidney transplant recipients, based upon data demonstrating that continuing glucocorticoid therapy reduces the risk of acute rejection and chronic allograft nephropathy compared with glucocorticoid withdrawal [<a href="#rid15">15-17</a>]. Some centers may choose to use long-term glucocorticoids in patients who are receiving a second transplant, who have a high panel of reactive antibody (PRA), or who have an immunologic cause for chronic kidney disease requiring glucocorticoids. Alternatively, some centers may choose to withdraw glucocorticoids early after transplant (within weeks to months) in patients at low to moderate risk for rejection to minimize toxicity and decrease overall immunosuppression. Long-term patient and allograft survival with this approach have been shown to be similar to that with glucocorticoid continuation [<a href="#rid14">14,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Assessment of immunologic risk'</a>.)</p><p></p><p class="bulletIndent1">It is less clear whether late glucocorticoid withdrawal (greater than one year posttransplant) should or should not be performed. Late withdrawal has been successfully performed in some centers, but its effect upon long-term allograft function and the risk of chronic rejection has not been conclusively evaluated [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1">Several randomized trials have compared outcomes with glucocorticoid continuation and glucocorticoid withdrawal/avoidance [<a href="#rid14">14-17,20</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review of 48 randomized trials (7803 patients) comparing glucocorticoid avoidance or withdrawal with glucocorticoid maintenance, or comparing glucocorticoid avoidance with glucocorticoid withdrawal, found no significant difference in patient mortality or allograft loss at one year posttransplant among adults [<a href="#rid15">15</a>]. However, the risk of acute rejection at one year was higher in patients treated with glucocorticoids for fewer than 14 days after transplantation (relative risk [RR] 1.58, 95% CI 1.08-2.30) and in those who were withdrawn from glucocorticoids at a later time point after transplantation (RR 1.77, 95% CI 1.20-2.61). Continuation of glucocorticoids was not associated with a difference in harmful events, such as infection and malignancy, in adult kidney transplant recipients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial in 295 kidney transplant recipients that compared two immunosuppression minimization strategies (early glucocorticoid withdrawal from day 3 or reduced <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> exposure [ie, target trough level of 3 to 5 ng/mL] from six months after transplant) with standard immunosuppression with <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>, tacrolimus, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, and low-dose glucocorticoids, allograft function at 24 months was comparable between the treatment groups [<a href="#rid16">16</a>]. Patients in the early glucocorticoid withdrawal group had a higher frequency of treated rejection compared with those in the tacrolimus minimization and standard immunosuppression groups (24 versus 11 and 14 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Longer-term outcomes were reported in a randomized trial that compared very early glucocorticoid withdrawal with low-dose, long-term glucocorticoid therapy in 386 low- to moderate-risk kidney transplant recipients [<a href="#rid14">14,17</a>]. All patients received induction therapy with either <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-Thymoglobulin (68 percent) or interleukin (IL) 2 receptor antibody (32 percent); maintenance therapy consisted of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), and seven days of glucocorticoids followed by either glucocorticoid withdrawal or continuation (taper to 5 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> by six months after transplant). At five years, there was no significant difference in the primary composite of death, allograft loss, or moderate/severe rejection between the groups. The early withdrawal group had a higher incidence of chronic allograft nephropathy (10 versus 4 percent) and biopsy-proven acute rejection (18 versus 11 percent). There were no significant differences in blood pressure, posttransplant diabetes mellitus (PTDM), serum cholesterol or low-density lipoprotein levels, or rates of bone fracture or cataracts. At a median of 15.8 years after transplant, the risks of all-cause and death-censored allograft failure were similar between the treatment groups [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Systemic glucocorticoids have adverse effects on many organ systems, including, but not limited to, hyperglycemia, fluid retention, hypertension, poor wound healing, osteoporosis, cataracts, and susceptibility to infection  (<a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">table 2</a>). These are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H21839797"><span class="h2">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>CNIs (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) are a cornerstone of immunosuppression in kidney and other solid organ transplantation. CNIs selectively inhibit calcineurin, thereby impairing the transcription of IL-2 and several other cytokines in T cells  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). By inhibiting cytokine gene transcription, CNIs suppress T cell and T cell-dependent B cell activation. Either tacrolimus or cyclosporine is used in over 90 percent of kidney transplant recipients in the United States, with tacrolimus being much more commonly used. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p>For most patients undergoing kidney transplantation, we suggest <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> rather than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> as the CNI of their maintenance immunosuppression regimen. Among kidney transplant recipients, tacrolimus is more effective than nonmodified and modified cyclosporine at lowering the rate of acute rejection [<a href="#rid8">8,9,21-27</a>]. Overall, allograft and patient survival rates are similar with the two agents [<a href="#rid10">10,21-23,25,26,28-30</a>], although some studies have shown superior allograft survival with tacrolimus [<a href="#rid8">8,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 30 trials (4102 patients) comparing <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (nonmodified and modified), tacrolimus lowered the risk of allograft loss at six months (RR 0.56, 95% CI 0.36-0.86) [<a href="#rid8">8</a>]. The benefit from tacrolimus was diminished when used at higher doses, possibly due to increased rates of CNI toxicity and infection. Allograft loss at later time points also favored tacrolimus (RR 0.77 [95% CI 0.58-1.02] at one year, 0.74 [95% CI 0.46-1.21] at two years, and 0.71 [95% CI 0.52-0.96] at three years). In addition, tacrolimus decreased the risk of acute rejection at one year (RR 0.66, 95% CI 0.6-0.79).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Efficacy Limiting Toxicity Elimination (ELITE)-Symphony trial, low-dose <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, and glucocorticoids (with daclizumab induction) produced higher 12-month allograft survival versus standard-dose and low-dose cyclosporine-based regimens and a low-dose sirolimus-based regimen (94 versus 93, 89, and 89 percent, respectively), although the difference with the low-dose <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> regimen was not statistically significant [<a href="#rid9">9</a>]. Rates of biopsy-proven acute rejection were lower among patients receiving low-dose tacrolimus than in those receiving standard or low-dose cyclosporine or low-dose <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (12 versus 26, 24, and 37 percent, respectively). However, higher rates of PTDM occurred in patients receiving low-dose tacrolimus (8 percent) versus those receiving standard-dose cyclosporine (6 percent) or low-dose cyclosporine (4 percent), and low-dose sirolimus (7 percent).</p><p></p><p class="headingAnchor" id="H84964943"><span class="h3">Tacrolimus</span><span class="headingEndMark"> — </span>Most patients undergoing kidney transplantation receive <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> as part of their maintenance immunosuppression regimen [<a href="#rid5">5</a>]. Tacrolimus is associated with lower acute rejection rates and similar overall costs compared with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid8">8,28</a>]. In addition, despite higher rates of PTDM, tacrolimus is better tolerated and preferred by patients compared with cyclosporine. Tacrolimus, unlike cyclosporine, does not lower <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> levels, and therefore, relatively lower doses of mycophenolate are needed when tacrolimus is used. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations </strong>– <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> is available in oral, sublingual, and intravenous formulations. The available oral formulations include immediate-release capsules and two extended-release oral formulations (capsules [Astagraf XL, Advagraf] and tablets [Envarsus]) designed for once-daily administration. The efficacy and safety of immediate-release and extended-release tacrolimus formulations are comparable [<a href="#rid31">31-36</a>]. However, there are important pharmacokinetic differences between these formulations, particularly between extended-release tacrolimus tablets (Envarsus) and both immediate-release and extended-release capsules (Astagraf XL, Advagraf). Extended-release tacrolimus tablets (Envarsus) have a higher drug exposure per milligram basis, lower peak concentrations, and a longer time to maximum concentration than immediate-release tacrolimus and extended-release tacrolimus capsules (Astagraf XL, Advagraf) [<a href="#rid37">37</a>]. Thus, a 20 to 30 percent dose reduction is recommended when converting from immediate-release and extended-release capsules (Astagraf XL, Advagraf) to extended-release tablets (Envarsus)  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). Adverse effects of extended-release tacrolimus appear to be similar to those of immediate-release tacrolimus, with the exception of fewer tremors [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Tacrolimus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Initial dosing of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> may vary from center to center. Suggested dosing and dose conversions for tacrolimus is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Dose'</a> and  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Administration'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– The adverse effects of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are generally similar and include nephrotoxicity, hypertension, neurotoxicity, electrolyte abnormalities (hyperkalemia, hypomagnesemia), metabolic abnormalities (hyperlipidemia, PTDM), infections, and an increased risk of malignancy. These are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">Compared with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is associated with more frequent neurologic side effects (such as tremor and headache), gastrointestinal side effects (diarrhea, dyspepsia, and vomiting), and alopecia, and a higher incidence of PTDM. (See  <a class="medical medical_review" href="/z/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus", section on 'Modifiable risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H3911477029"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is an alternative CNI for patients who have or who are predisposed to tacrolimus-associated toxicity. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations</strong> – <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is available in nonmodified and modified formulations. Modified cyclosporine is an oral preparation of cyclosporine that involves a unique microemulsion formulation. The microemulsion is miscible in water and has improved pharmacokinetic bioavailability and less intra- and interindividual variability when compared with the standard nonmodified oral preparation [<a href="#rid38">38-43</a>]. We and most centers administer modified cyclosporine because of equivalent efficacy and more convenient administration and monitoring compared with nonmodified cyclosporine [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Cyclosporine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Initial dosing of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may vary from center to center. Suggested dosing for cyclosporine is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Dose'</a> and  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Administration'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– The adverse effects of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are generally similar and include nephrotoxicity, hypertension, neurotoxicity, electrolyte abnormalities (hyperkalemia, hypomagnesemia), metabolic abnormalities (hyperlipidemia, PTDM), infections, and an increased risk of malignancy. These are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">Compared with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is associated with more frequent hirsutism, gingival hyperplasia, and hypertension.</p><p></p><p class="headingAnchor" id="H625976483"><span class="h2">Antimetabolites</span><span class="headingEndMark"> — </span>Antimetabolite agents interfere with the synthesis of nucleic acids and inhibit the proliferation of both T and B lymphocytes  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). MMF or enteric-coated <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium (EC-MPS) is the antimetabolite agent used in more than 90 percent of kidney transplant recipients in the United States; <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> is rarely used [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a>.)</p><p>For most kidney transplant recipients, we suggest <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (MMF or EC-MPS) rather than <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> as the antimetabolite of their maintenance immunosuppression. The preference for mycophenolate as an antimetabolite is based upon multiple large trials and meta-analyses showing lower acute rejection rates, and possibly improved graft survival, with MMF as compared with azathioprine [<a href="#rid48">48-59</a>]. The best data come from a 2015 systematic review of 23 trials (3301 kidney transplant recipients) that compared the efficacy and safety of MMF versus azathioprine [<a href="#rid48">48</a>]. Compared with azathioprine, MMF reduced the risk of death-censored graft loss (RR 0.78, 95% CI 0.62-0.99), acute rejection (RR 0.65, 95% CI 0.57-0.73), and chronic allograft nephropathy (RR 0.69, 95% CI 0.48-0.99). There were no significant differences in all-cause mortality. Although there was no difference in cytomegalovirus (CMV) viremia or CMV syndrome, the risk of tissue-invasive CMV disease was higher with MMF (RR 1.7, 95% CI 1.1-2.6). Gastrointestinal symptoms (eg, diarrhea) were more common with MMF, whereas thrombocytopenia and elevated liver enzymes were more common with azathioprine. Nearly all of these studies compared azathioprine with MMF when used in combination with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (mostly nonmodified). This may not necessarily be relevant to the combination of MMF plus <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, which is the most common combination of an antimetabolite plus a CNI.</p><p class="headingAnchor" id="H3722687755"><span class="h3">Mycophenolate</span><span class="headingEndMark"> — </span>Most patients undergoing kidney transplantation receive <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (MMF or EC-MPS) as the antimetabolite of their maintenance immunosuppression [<a href="#rid5">5</a>]. Despite its increased cost, mycophenolate is preferred over <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> because of its superior ability to prevent acute rejection and better side effect profile [<a href="#rid48">48</a>]. However, mycophenolate should <strong>not </strong>be used in female transplant recipients of childbearing age unless they are on long-acting contraception, have undergone surgical sterilization procedures, or have absolute infertility. Mycophenolate is teratogenic, and its use is contraindicated in pregnancy. Thus, in these patients, we prefer to use azathioprine, which does not seem to have a detrimental effect on fertility or pregnancy [<a href="#rid60">60</a>]. (See <a class="local">'Pregnancy and lactation'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations </strong>– Oral <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> is available in two different formulations: MMF and EC-MPS. MMF and EC-MPS are similar in efficacy and safety [<a href="#rid61">61-66</a>]. We prefer EC-MPS over MMF because EC-MPS may be associated with fewer gastrointestinal side effects among certain groups of patients (eg, patients with indigestion, diabetes, those treated with glucocorticoids, or patients converted from MMF to EC-MPS between 6 to 12 months posttransplant) [<a href="#rid66">66,67</a>]. If patients tolerate neither MMF nor EC-MPS, we switch to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. (See <a class="local">'Azathioprine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Suggested dosing for MMF and EC-MPS is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">In the patient with marked gastrointestinal side effects with MMF, we first switch to EC-MPS from MMF at a molecularly equivalent dose (250 mg of MMF is equivalent to 180 mg of EC-MPS). If that is ineffective, we lower the dose of EC-MPS further or consider switching to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– The most common adverse effects of MMF and EC-MPS include bone marrow suppression and gastrointestinal disturbances (eg, persistent diarrhea, nausea, abdominal cramping). These symptoms are generally dose-related and improve with temporary or permanent dose reduction. (See  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H4008847491"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> can be used for patients who do not tolerate <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> and for female patients who are pregnant or may become pregnant (ie, those without effective long-acting contraception, surgical sterilization, or infertility). (See <a class="local">'Pregnancy and lactation'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Suggested dosing for <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Leukopenia is the most serious side effect of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. The immunosuppressive effect of azathioprine is not related to the reduction in white blood cell count; as a result, it is not necessary to increase the dose to achieve leukopenia. Azathioprine should be temporarily withheld, not just dose-reduced, if the white cell count falls below 3000/mm<sup>3</sup> or if the count drops by 50 percent between blood draws. Recovery usually occurs within one to two weeks. The drug can then be restarted at a lower dose and increased gradually to the usual maintenance dose while monitoring the white cell count. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">The toxicity of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> is primarily related to the activity of the enzyme thiopurine methyltransferase (TPMT), and deficiency of this enzyme has been associated with significant bone marrow suppression. We do not routinely test for TPMT deficiency before beginning azathioprine but perform testing in patients who develop severe myelosuppression while taking azathioprine. If the patient is found to have TPMT deficiency, we discontinue azathioprine. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Pharmacogenetics and azathioprine toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H419534703"><span class="h2">mTOR inhibitors</span><span class="headingEndMark"> — </span>Mechanistic (mammalian) target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) are structurally similar to CNIs but exert their immunosuppressive effects through calcineurin-independent mechanisms. They bind to the FK-binding protein and block the activity of a cytoplasmic protein kinase called mTOR, thereby interrupting DNA and protein synthesis and proliferation of T, natural killer, and B cells  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). mTOR inhibitors are generally used as alternative agents in patients who cannot continue taking a CNI due to toxicity, who develop a new cancer after transplantation, or who are nonadherent with therapy. (See <a class="local">'Calcineurin inhibitor-related toxicity'</a> below and  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Suggested dosing for <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> are associated with several possible adverse effects including bone marrow suppression, dyslipidemia, poor wound healing, and, among kidney transplant recipients, an increased risk of posttransplant mortality [<a href="#rid68">68-70</a>]. These are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– The efficacy and safety of mTOR inhibitors in kidney transplant recipients have been evaluated in multiple trials and systematic reviews [<a href="#rid71">71-79</a>]. Most of these studies have examined the use of mTOR inhibitors as a replacement for either CNIs or antimetabolite agents or in combination with CNIs. Overall, none of these trials have shown any improvement in patient or allograft survival with regimens that included mTOR inhibitors, while retrospective studies of large databases have found inferior long-term allograft survival with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid71">71-73,79</a>]. In addition, one meta-analysis found that sirolimus-based immunosuppression was associated with a decreased risk of malignancy but an increased risk of posttransplant mortality when compared with CNI-based strategies. The best evidence comes from the following three systematic reviews:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review of 33 randomized trials examined the use of mTOR inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) as a replacement for either CNIs or antimetabolic agents or in combination with CNIs [<a href="#rid74">74</a>]. There was <strong>no </strong>significant difference in allograft or patient survival with any comparison. Compared with patients who received a CNI, those who received an mTOR inhibitor had better kidney function for up to two years posttransplant but also had an increased risk of bone marrow suppression, dyslipidemia (RR 1.8, 95% CI 1.1-3.0), and lymphoceles (RR 3.1, 95% CI, 1.6-5.9).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conversion from a CNI to an mTOR inhibitor among kidney transplant recipients was evaluated in a systematic review of 29 randomized trials [<a href="#rid75">75</a>]. Patients who were converted from a CNI to an mTOR inhibitor within one year posttransplant had a higher glomerular filtration rate (GFR) at one year compared with those who remained on a CNI. However, there was no difference in graft survival, and patients who switched to an mTOR inhibitor had a higher risk of acute rejection up to one year posttransplant (RR 1.72, 95% CI 1.34-2.22) as well as a higher risk of dyslipidemia and infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another systematic review and meta-analysis of 21 randomized trials examined the risk of malignancy and death among 5876 kidney and kidney-pancreas transplant recipients who received immunosuppressive regimens either with or without <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid76">76</a>]. Compared with controls, sirolimus was associated with a decreased risk of malignancy (adjusted hazard ratio [aHR] 0.60, 95% CI 0.39-0.93) but an increased risk of death (aHR 1.43, 95% CI 1.21-1.71). The increased mortality was driven by increased cardiovascular and infection-related deaths in the sirolimus group.</p><p></p><p class="headingAnchor" id="H62453201"><span class="h2">Belatacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">Belatacept</a> is a fusion protein composed of the Fc fragment of human immunoglobulin G1 linked to the extracellular domain of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) that selectively inhibits T cell activation through costimulatory blockade  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). Belatacept is administered intravenously. Its use is generally reserved for patients who cannot continue taking a CNI due to toxicity or who are nonadherent to therapy due to pill burden [<a href="#rid6">6</a>]. A few centers have used belatacept with a time-limited course of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> as part of an initial maintenance regimen to avoid long-term use of CNIs and their associated adverse effects [<a href="#rid11">11,12</a>]; however, more data are needed. </p><p><a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">Belatacept</a> should <strong>not</strong> be administered to patients who are Epstein-Barr virus (EBV)-seronegative and who received a transplant from an EBV-seropositive donor or to recipients with unknown EBV status because of the risk of EBV-associated posttransplant lymphoproliferative disorder (PTLD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– Dosing for <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> (when converting from a CNI) is provided in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">Belatacept</a> is associated with an increased risk of EBV-associated PTLD. Other common adverse effects include edema, hypertension, headache, diarrhea, constipation, anemia, and cough.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Evidence evaluating the use of <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> in kidney transplant recipients can be divided into studies examining use of belatacept as initial maintenance immunosuppression (de novo use) and those examining conversion from a CNI-based regimen to a belatacept-based regimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>De novo use </strong>– Multiple studies have evaluated the efficacy and safety of <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> as part of an initial maintenance immunosuppressive regimen in kidney transplant recipients [<a href="#rid80">80-92</a>]. As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Two large trials have compared de novo <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> with cyclosporine-based triple immunosuppression. In the Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT), 666 recipients of a living or standard-criteria deceased donor kidney transplant were randomly assigned to more intensive belatacept, less intensive belatacept, or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, in conjunction with MMF and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>; all patients received <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> as induction therapy [<a href="#rid81">81,89</a>]. At 12 months, patients receiving belatacept had a higher incidence and grade of acute rejection (22 and 17 versus 7 percent in the more intensive belatacept, less intensive belatacept, and cyclosporine arms, respectively) but had better allograft function, a benefit that was sustained at seven years posttransplant (estimated GFR of 70 and 72 versus 45 mL/min/1.73 m<sup>2</sup>, respectively). In addition, rates of death or allograft loss were significantly lower at seven years in patients assigned to belatacept (12.7 and 12.8 versus 21.7 percent). PTLD was more common with belatacept, particularly among EBV-seronegative patients.</p><p></p><p class="bulletIndent3">The BENEFIT-EXT trial compared the efficacy and safety of <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> with that of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in expanded criteria donor kidney transplant recipients, using the same study design as the one used in BENEFIT [<a href="#rid82">82,93</a>]. At 12 months, acute rejection rates were similar between groups. Similar to BENEFIT, patients treated with belatacept had better kidney function at one and seven years compared with those treated with cyclosporine. Rates of PTLD were also higher among patients treated with belatacept.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Two trials have compared <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> with a more contemporary tacrolimus-based regimen. One small trial comparing belatacept with a tacrolimus-based, glucocorticoid-containing regimen (all patients received MMF and <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> as well as <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> for induction) found a higher incidence of acute rejection at one year posttransplant among patients receiving belatacept (55 versus 10 percent) and no different in allograft function between the two groups [<a href="#rid94">94</a>]. Allograft loss, due to rejection, occurred in three patients, all in the belatacept group. </p><p></p><p class="bulletIndent3">In a larger trial that compared <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> with a tacrolimus-based, glucocorticoid-avoiding regimen, 316 kidney transplant recipients were randomly assigned to belatacept with <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> induction, belatacept with rATG-Thymoglobulin induction, or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> with rATG-Thymoglobulin induction; all patients received <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (MMF or EC-MPS) and a five-day glucocorticoid taper [<a href="#rid92">92,95</a>]. At two years posttransplant, patient and graft survival rates were similar among the groups. However, rates of biopsy-proven acute rejection were higher in the belatacept treatment groups than in the tacrolimus group (19 and 25 versus 7 percent).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective single-center analysis compared outcomes among 535 kidney transplant recipients treated with <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> and a historical cohort of 205 recipients receiving a tacrolimus-based regimen; all patients also received MMF and glucocorticoids and induction therapy with <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> [<a href="#rid12">12</a>]. Rates of biopsy-proven acute rejection at one year were higher among patients receiving belatacept (51 versus 21 percent). The addition of a nine-month course of low-dose <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> to belatacept decreased the incidence of acute rejection to 16 percent, a rate similar to that observed in the tacrolimus group. Patient and allograft survival at four years were similar between the groups. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Conversion to </strong><strong>belatacept</strong><strong> </strong>– Data on the efficacy and safety of switching from a CNI-based regimen to <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> come from two randomized trials and observational studies [<a href="#rid90">90,96-100</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In one randomized trial in 446 kidney transplant recipients who were 6 to 60 months posttransplant and had stable allograft function on CNI-based immunosuppression, 24-month patient and graft survival were similar between patients assigned to switch to <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> and those who were assigned to continue CNI treatment (98 and 97 percent, respectively) [<a href="#rid100">100</a>]. The belatacept conversion group had higher rates of biopsy-proven acute rejection (8 versus 4 percent) but lower rates of de novo donor-specific antibody formation (1 versus 7 percent). Estimated GFR at 24 months was higher with belatacept (55 versus 48 mL/min/1.73 m<sup>2</sup>). Serious adverse events and infections were similar between the groups; one patient in the belatacept group developed PTLD.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Similar findings were reported in another randomized trial in 173 stable kidney transplant recipients who were 6 to 36 months posttransplant on a CNI-based regimen [<a href="#rid90">90,96</a>]. Compared with patients who continued CNI treatment, those who switched to <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> had better allograft function at 12 and 36 months but also higher rates of acute rejection. While overall rates of serious adverse events were similar between the groups, more viral and fungal infections occurred in the belatacept group.</p><p></p><p class="bulletIndent2">A higher rate of opportunistic infections (particularly CMV disease and <em>Pneumocystis</em> pneumonia) with <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> conversion has also been reported in observational studies [<a href="#rid97">97-99</a>].</p><p></p><p class="headingAnchor" id="H4084776206"><span class="h1">DRUG MONITORING</span><span class="headingEndMark"> — </span>Kidney transplant recipients routinely undergo drug monitoring to achieve proper dosing and to avoid over-immunosuppression and drug toxicity. The frequency of monitoring varies depending upon the time posttransplant and transplant center protocol. </p><p>Monitoring and target levels for <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> are presented in the table  (<a class="graphic graphic_table graphicRef143738" href="/z/d/graphic/143738.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'</a>.)</p><p>For patients on <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), monitoring of drug levels is not generally performed. Measuring trough levels of mycophenolic acid (the active metabolite of MMF) has not been shown to correlate well with drug exposure [<a href="#rid101">101,102</a>]. Area under the curve of mycophenolic acid is considered the standard for monitoring mycophenolic acid levels, but technical challenges (eg, the need for multiple blood samples at different time points) limit its use in clinical practice.</p><p class="headingAnchor" id="H1808585862"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Several agents used for maintenance immunosuppressive therapy have drug interactions that may necessitate dose adjustments  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). A discussion of some of the more commonly encountered drug interactions seen in transplant patients is presented below. For additional information on drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitors</strong> – Calcineurin inhibitors (CNIs; <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) are substrates of cytochrome P450 CYP3A drug metabolism and P-glycoprotein (P-gp) transport. Thus, any drug that affects CYP3A4 metabolism or P-gp transport can potentially interact with CNIs and thereby cause either overdosing, with deterioration of kidney function, or underdosing, with an increased risk of rejection  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Food and drug interactions'</a>.)</p><p></p><p class="bulletIndent1">Common medications that increase blood levels of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium channel blockers – <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, and <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Antifungal agents – <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, and <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotics – <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a></p><p class="bulletIndent2"><span class="glyph">•</span>Antiviral agents – <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> and ritonavir-containing coformulations</p><p class="bulletIndent2"><span class="glyph">•</span>Grapefruit juice</p><p></p><p class="bulletIndent1">Common medications that decrease blood levels (by inducing hepatic metabolism) include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticonvulsants – <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Antimicrobials – <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a></p><p></p><p class="bulletIndent1">Other nephrotoxins may worsen the kidney toxicity of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, such as nonsteroidal antiinflammatory drugs (NSAIDs), aminoglycosides, and amphotericin B. In addition, hydroxymethylglutaryl coenzyme A reductase inhibitors (such as <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>) can cause rhabdomyolysis and, rarely, acute kidney injury, when given with cyclosporine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong> – <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF) is metabolized by cytochrome P450 CYP3A4/5 and probably by cytochrome P450 CYP2C8. Common drug interactions with mycophenolate in transplant recipients include the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coadministration of proton pump inhibitors (eg, <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a>, <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">lansoprazole</a>) and MMF may result in lower mycophenolic acid exposure, which could increase the risk of acute rejection [<a href="#rid103">103-109</a>]. However, other studies have not supported these findings [<a href="#rid110">110-112</a>]. Enteric-coated <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium (EC-MPS) appears less likely to interact. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should avoid taking aluminum or <a class="drug drug_general" data-topicid="9582" href="/z/d/drug information/9582.html" rel="external">magnesium hydroxide</a> antacids at the same time as MMF or EC-MPS since these drugs decrease the area under the curve of mycophenolic acid by approximately 17 percent. Patients who are on <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">sevelamer</a> should take this medication two hours after MMF or EC-MPS since sevelamer can decrease the exposure and maximum concentration of mycophenolic acid. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trough levels of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> appear to be lowered by the concurrent administration of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid113">113-115</a>], an effect that is not observed with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Tacrolimus inhibits UDP-glucuronosyltransferase, the enzyme that metabolizes mycophenolic acid (the active metabolite of MMF and EC-MPS), thereby increasing concentrations of mycophenolic acid. If tacrolimus is substituted for cyclosporine in a patient concurrently taking mycophenolate, we frequently decrease the dose of mycophenolate by 50 percent. Although the use of tacrolimus compared with cyclosporine increases MMF exposure by 20 to 30 percent, we believe that a 50 percent reduction is appropriate since, compared with a 25 percent reduction, it may be associated with fewer gastrointestinal side effects and anemia, and it may also limit the costs of an enhanced pill burden. EC-MPS at a dose of 360 mg two times per day in a patient receiving tacrolimus is generally equivalent to 720 mg two times per day in a patient receiving cyclosporine. (See  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong> – Severe leukopenia can occur if xanthine oxidase inhibitors such as <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> or <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a> (used for the treatment of hyperuricemia and gout) are given with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. Allopurinol and febuxostat inhibit the activity of xanthine oxidase, which also plays a role in the metabolism of azathioprine. Thus, allopurinol and febuxostat should generally be <strong>avoided</strong> in patients treated with azathioprine. If, however, the patient has severe gout and either allopurinol or febuxostat must be used, we reduce the azathioprine dose (by at least 50 percent) and carefully monitor the white blood cell count. Even with this approach, however, azathioprine may need to be discontinued. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>mTOR inhibitors </strong>– <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> are substrates of cytochrome P450 CYP3A drug metabolism. Thus, coadministration of these agents with cytochrome P450 3A inducers (such as some anticonvulsants, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, St. John's wort) and with cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Drug interactions'</a>.)</p><p></p><p class="headingAnchor" id="H3856971121"><span class="h1">WHEN AND HOW TO MODIFY THERAPY</span><span class="headingEndMark"> — </span>In most kidney transplant recipients, a stable maintenance immunosuppression regimen is established within the first three months after transplantation. After three months, we do not routinely reduce maintenance immunosuppression, even among stable patients. Some centers may continue to reduce maintenance immunosuppression at six months and up to one year posttransplant. Complete withdrawal of all maintenance therapy is <strong>not</strong> recommended (except in recipients of human leukocyte antigen [HLA]-identical allografts from a monozygotic twin), since it frequently leads to late acute rejection or accelerated chronic rejection. These complications most often occur in patients who are not adherent to therapy or who cannot afford to pay for the medications. (See <a class="local">'Patients with nonadherence to therapy'</a> below.)</p><p>However, some patients may require a modification of the initial maintenance immunosuppression regimen due to the development of posttransplant complications (eg, toxicity, allograft failure, acute rejection, infection, cancer) or other clinical events (eg, pregnancy, surgery). A discussion of these special patient populations is presented below.</p><p class="headingAnchor" id="H137698060"><span class="h2">Calcineurin inhibitor-related toxicity</span><span class="headingEndMark"> — </span>Although calcineurin inhibitors (CNIs) are a fundamental component of maintenance immunosuppression in kidney transplantation, some patients are unable to tolerate these agents due to nephrotoxicity or other adverse effects. Alternative immunosuppression regimens involving the use of mechanistic (mammalian) target of rapamycin (mTOR) inhibitors or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>, a costimulatory blockade agent, have been designed to try to reduce toxicity while maintaining effective immunosuppression in these patients. </p><p>In patients with CNI-related toxicity, our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have biopsy-proven CNI nephrotoxicity (without acute rejection), we typically discontinue the CNI and switch to either an mTOR inhibitor (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>. (See <a class="local">'mTOR inhibitors'</a> above and <a class="local">'Belatacept'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who develop other serious adverse effects (eg, neurotoxicity, thrombotic microangiopathy) that can be attributed to CNIs, we first reduce the dose of the CNI by 25 to 50 percent. If the adverse effects persist in spite of dose reduction, we discontinue the CNI and switch to either an mTOR inhibitor (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>. (See <a class="local">'mTOR inhibitors'</a> above and <a class="local">'Belatacept'</a> above.)</p><p></p><p>The decision to use an mTOR inhibitor or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> depends upon multiple factors and must be made on an individual patient basis. Adverse drug reactions, drug interactions, efficacy, convenience, and cost must all be considered. Treatment with belatacept, for example, requires intravenous access, close proximity to an infusion center, and the ability to pay for this high-cost medication. In addition, belatacept may increase the risk of posttransplant lymphoproliferative disorder. Thus, we only use belatacept in Epstein-Barr virus (EBV)-seropositive patients. We generally avoid mTOR inhibitors in patients who have preexisting precautions or contraindications to these medications.</p><p class="headingAnchor" id="H3374948687"><span class="h2">Pregnancy and lactation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF), enteric-coated mycophenolate sodium (EC-MPS), and mTOR inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) should be <strong>avoided</strong> during pregnancy and in patients who may become pregnant. <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> has been used safely in pregnant transplant patients. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> also appear to be safe. Pharmacokinetic factors, such as volume of distribution and metabolism, are altered with pregnancy, and drug levels require more frequent monitoring and adjustment. These issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113826.html" rel="external">"Sexual and reproductive health after kidney transplantation", section on 'Management of immunosuppression'</a> and  <a class="medical medical_review" href="/z/d/html/113826.html" rel="external">"Sexual and reproductive health after kidney transplantation", section on 'Breastfeeding'</a>.)</p><p class="headingAnchor" id="H2812123310"><span class="h2">Patients unable to take oral medications</span><span class="headingEndMark"> — </span>Patients who are unable to<strong> </strong>take oral medications can be treated with intravenous formulations. Intravenous formulations are available for <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, MMF, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>. Patients who are taking EC-MPS can be switched to intravenous MMF. There are no intravenous formulations for <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. Suggested conversion from oral to intravenous formulations is detailed in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>). Patients should be transitioned back to oral therapy as soon as tolerated. </p><p>Some centers prefer to use sublingual rather than intravenous <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> when patients are nil per os (eg, in the postoperative setting). One study found that a slightly higher dose of oral tacrolimus may be needed when converting from sublingual to oral tacrolimus [<a href="#rid116">116</a>]. Suggested conversion from oral to sublingual tacrolimus is detailed in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1249618997"><span class="h2">Patients with acute rejection</span><span class="headingEndMark"> — </span>An important issue is the optimal immunosuppressive strategy among patients with acute rejection. Among such patients who are being administered triple immunosuppressive therapy, we switch to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (if they are on <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (if they are on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>). Patients who develop acute rejection while on triple therapy with tacrolimus, mycophenolate, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> should continue these agents at higher doses if possible. We typically start by targeting higher levels of tacrolimus (ie, 5 to 7 ng/mL). Patients who are receiving dual therapy (CNI and antimetabolite without prednisone) at the time of rejection should be initiated on long-term prednisone at 5 mg once daily.</p><p>Patients with recurrent rejection may be nonadherent to their maintenance immunosuppression, and factors contributing to poor adherence should be assessed. (See <a class="local">'Patients with nonadherence to therapy'</a> below.)</p><p>The treatment of patients with acute T cell-mediated (cellular) rejection and antibody-mediated rejection is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a> and  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p class="headingAnchor" id="H2154942833"><span class="h2">Patients who develop infection</span><span class="headingEndMark"> — </span>The protocol for adjusting the immunosuppressive regimen among patients who develop infection varies among institutions but generally depends upon the severity of infection. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with life-threatening infections or evidence of sepsis, we withhold all immunosuppressive agents, except for low-dose glucocorticoids. We usually restart the CNI within one week from the time it was withheld but discontinue the antimetabolite indefinitely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with moderate infection (ie, who require admission and intravenous antibiotics but are not septic), we withhold one agent (typically the antimetabolite, such as <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>). We usually hold this agent for four to six weeks and restart it at 50 percent of the dose that was administered prior to the infection. In patients with recurrent infection, we discontinue the antimetabolite indefinitely. Some clinicians do not alter the immunosuppressive regimen among patients with moderately severe bacterial infection but decrease the glucocorticoid dose among patients with moderately severe fungal infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In otherwise stable patients who develop community-acquired infections (eg, bronchitis, pneumonia, cystitis, cellulitis), we generally do not modify the maintenance immunosuppression regimen.</p><p></p><p>The adjustment of immunosuppression among patients with cytomegalovirus (CMV) or BK polyomavirus infection is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Reduction of immunosuppression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy", section on 'Reduction of immunosuppression'</a>.)</p><p></p><p class="headingAnchor" id="H2468460394"><span class="h2">Patients with a new cancer</span><span class="headingEndMark"> — </span>In kidney transplant recipients who develop a new cancer after transplantation, we typically reduce maintenance immunosuppression, which may result in regression of some types of tumors. The modification of maintenance immunosuppression in patients who develop a posttransplant malignancy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation", section on 'Reduction in immunosuppression'</a> and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p class="headingAnchor" id="H535469031"><span class="h2">Patients undergoing nontransplant surgery</span><span class="headingEndMark"> — </span>Most kidney transplant recipients who undergo elective surgery do <strong>not</strong> require modification of their maintenance immunosuppressive therapy. As an exception, patients who are taking an mTOR inhibitor are at increased risk for delayed wound healing, and therefore, we typically hold the mTOR inhibitor for one week prior to surgery and switch to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. When the surgical incision has healed, we discontinue tacrolimus and restart the mTOR inhibitor. If a kidney transplant recipient undergoing elective surgery is unable to take oral medications in the perioperative setting, we typically convert the immunosuppressive agents to the intravenous formulation until the patient is able to resume taking oral medications. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Switching formulations'</a>.)</p><p class="headingAnchor" id="H917670255"><span class="h2">Patients with a failing allograft</span><span class="headingEndMark"> — </span>In general, maintenance immunosuppression should be reduced in a patient with a failing allograft. The modification of immunosuppression in patients with a failing allograft is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7320.html" rel="external">"Kidney transplantation in adults: Management of the patient with a failed kidney transplant", section on 'Management of immunosuppression'</a>.)</p><p class="headingAnchor" id="H179863137"><span class="h2">Patients with nonadherence to therapy</span><span class="headingEndMark"> — </span>Nonadherence is a risk factor for rejection and allograft loss [<a href="#rid68">68-70</a>]. Thus, every effort should be made to identify nonadherent patients early and provide them with appropriate counseling and assistance. In patients who are known to be nonadherent with therapy, modification of the maintenance immunosuppression regimen to simplify dosing or reduce pill burden may improve adherence. As an example, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> has a long half-life that permits convenient once-daily dosing. <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">Belatacept</a> is another option with its less frequent (monthly) administration. Alternatively, a regimen of extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> provides three immunosuppressive medications with once-daily dosing. Deciding upon an alternative regimen must be made on an individual patient basis, considering factors such as adverse drug reactions, drug interactions, efficacy, convenience, and cost.</p><p class="headingAnchor" id="H2241975020"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Practically all kidney transplant recipients require immunosuppressive therapy to prevent rejection and loss of the allograft  (<a class="graphic graphic_figure graphicRef143008" href="/z/d/graphic/143008.html" rel="external">figure 1</a>). Most patients receive induction therapy at the time of transplantation, followed by maintenance immunosuppression, which is initiated during the hospital stay and continued for the life of the allograft. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to maintenance therapy </strong>– For most kidney transplant recipients, we suggest a maintenance regimen consisting of triple immunosuppression therapy with a calcineurin inhibitor (CNI), an antimetabolite, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, rather than alternative regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We aim for the following regimen (see <a class="local">'Approach to maintenance therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcineurin inhibitor </strong>– For most kidney transplant recipients, we suggest <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> rather than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> as the CNI of their maintenance immunosuppression regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Tacrolimus is associated with lower acute rejection rates and is generally better tolerated than cyclosporine. (See <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antimetabolite </strong>– For most kidney transplant recipients, we suggest <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (mycophenolate mofetil [MMF] or enteric-coated mycophenolate sodium [EC-MPS]) rather than <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> as the antimetabolite of their maintenance immunosuppression regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Mycophenolate is preferred over azathioprine because of its superior ability to prevent acute rejection and its better side effect profile. However, mycophenolate is teratogenic, and we do <strong>not </strong>use mycophenolate in female recipients of childbearing age unless they are on long-acting contraception, have undergone surgical sterilization procedures, or have absolute infertility. In these patients, we prefer to use azathioprine. (See <a class="local">'Antimetabolites'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids </strong>– Glucocorticoid regimens vary among transplant recenters, and there is no consensus on the optimal dose or maintenance schedule following kidney transplantation. At our center, patients receive intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> at the time of transplantation, followed by a rapid taper of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to a dose of 5 mg/day by one month after transplant. For most kidney transplant recipients, we suggest continuing maintenance glucocorticoids indefinitely (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Some centers may choose to use long-term glucocorticoids in patients that are receiving a second transplant, who have a high panel of reactive antibody (PRA), or who have an immunologic cause for chronic kidney disease requiring glucocorticoids. Alternatively, some centers may choose to withdraw glucocorticoids in patients at low to moderate risk for rejection to minimize toxicity and decrease overall immunosuppression. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1">Suggested dosing of these agents is presented in the table  (<a class="graphic graphic_table graphicRef143860" href="/z/d/graphic/143860.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">We do not routinely use a mechanistic (mammalian) target of rapamycin (mTOR) inhibitor (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> as part of an initial maintenance immunosuppression regimen. However, such agents may be used as an alternative in patients who cannot continue taking a CNI due to toxicity, who develop a new cancer after transplantation, or who are nonadherent with therapy. (See <a class="local">'mTOR inhibitors'</a> above and <a class="local">'Belatacept'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug monitoring and interactions </strong>– Kidney transplant recipients routinely undergo drug monitoring to achieve proper dosing and to avoid over-immunosuppression and drug toxicity. Monitoring and target levels for specific agents are presented in the table  (<a class="graphic graphic_table graphicRef143738" href="/z/d/graphic/143738.html" rel="external">table 3</a>). Several agents used for maintenance immunosuppressive therapy have drug interactions that may necessitate dose adjustments  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). (See <a class="local">'Drug monitoring'</a> above and <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When and how to modify therapy </strong>– In most kidney transplant recipients, a stable maintenance regimen is established within the first three months after transplantation. After three months, we do not routinely reduce maintenance immunosuppression, even among stable patients. Complete withdrawal of all maintenance therapy is <strong>not</strong> recommended (except in recipients of human leukocyte antigen [HLA]-identical allografts from a monozygotic twin), since it frequently leads to late acute rejection or accelerated chronic rejection. Some patients may require a modification of the initial maintenance immunosuppression regimen due to the development of posttransplant complications (eg, toxicity, allograft failure, acute rejection, infection, cancer) or other clinical events (eg, pregnancy, surgery). (See <a class="local">'When and how to modify therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Krishnan N, Buchanan PM, Dzebisashvili N, et al. Monozygotic transplantation: concerns and opportunities. Am J Transplant 2008; 8:2343.</a></li><li><a class="nounderline abstract_t">Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. 1955. J Am Soc Nephrol 2001; 12:201.</a></li><li><a class="nounderline abstract_t">Weil R 3rd, Starzl TE, Porter KA, et al. Renal isotransplantation without immunosuppression. Ann Surg 1980; 192:108.</a></li><li><a class="nounderline abstract_t">Gumprich M, Woeste G, Kohlhaw K, et al. Living related kidney transplantation between identical twins. Transplant Proc 2002; 34:2205.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Nelson J, Alvey N, Bowman L, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. Pharmacotherapy 2022; 42:599.</a></li><li><a class="nounderline abstract_t">Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2:48.</a></li><li><a class="nounderline abstract_t">Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331:810.</a></li><li><a class="nounderline abstract_t">Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.</a></li><li><a class="nounderline abstract_t">Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834.</a></li><li><a class="nounderline abstract_t">Johnson AC, Zhang J, Karadkhele G, et al. Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation. Am J Transplant 2023.</a></li><li><a class="nounderline abstract_t">Adams AB, Goldstein J, Garrett C, et al. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. Am J Transplant 2017; 17:2922.</a></li><li><a class="nounderline abstract_t">Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 Annual Data Report: Kidney. Am J Transplant 2021; 21 Suppl 2:21.</a></li><li><a class="nounderline abstract_t">Woodle ES, Gill JS, Clark S, et al. Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients: Long-term Outcomes of a Randomized Clinical Trial. JAMA Surg 2021; 156:307.</a></li><li><a class="nounderline abstract_t">Haller MC, Royuela A, Nagler EV, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016; 2016:CD005632.</a></li><li><a class="nounderline abstract_t">van den Born JC, Meziyerh S, Vart P, et al. Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial. Transplantation 2023.</a></li><li><a class="nounderline abstract_t">Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.</a></li><li><a class="nounderline abstract_t">Arnol M, de Mattos AM, Chung JS, et al. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation 2008; 86:1844.</a></li><li><a class="nounderline abstract_t">Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8:294.</a></li><li><a class="nounderline abstract_t">Bae S, McAdams-DeMarco MA, Massie AB, et al. Panel-reactive Antibody and the Association of Early Steroid Withdrawal With Kidney Transplant Outcomes. Transplantation 2022; 106:648.</a></li><li><a class="nounderline abstract_t">Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318:1104.</a></li><li><a class="nounderline abstract_t">Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64:436.</a></li><li><a class="nounderline abstract_t">Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977.</a></li><li><a class="nounderline abstract_t">Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75:2048.</a></li><li><a class="nounderline abstract_t">Krämer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20:968.</a></li><li><a class="nounderline abstract_t">Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741.</a></li><li><a class="nounderline abstract_t">Azarfar A, Ravanshad Y, Mehrad-Majd H, et al. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis. Saudi J Kidney Dis Transpl 2018; 29:1376.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005; 80:41.</a></li><li><a class="nounderline abstract_t">Woodward RS, Kutinova A, Schnitzler MA, Brennan DC. Renal graft survival and calcineurin inhibitor. Transplantation 2005; 80:629.</a></li><li><a class="nounderline abstract_t">Irish W, Sherrill B, Brennan DC, et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 2003; 76:1686.</a></li><li><a class="nounderline abstract_t">Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7:595.</a></li><li><a class="nounderline abstract_t">Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10:2632.</a></li><li><a class="nounderline abstract_t">Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant 2014; 14:2796.</a></li><li><a class="nounderline abstract_t">Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant 2015; 29:796.</a></li><li><a class="nounderline abstract_t">Gaber AO, Alloway RR, Bodziak K, et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 2013; 96:191.</a></li><li><a class="nounderline abstract_t">Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013; 13:760.</a></li><li><a class="nounderline abstract_t">Tremblay S, Nigro V, Weinberg J, et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Am J Transplant 2017; 17:432.</a></li><li><a class="nounderline abstract_t">Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996; 62:759.</a></li><li><a class="nounderline abstract_t">Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57:1178.</a></li><li><a class="nounderline abstract_t">Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83:444.</a></li><li><a class="nounderline abstract_t">Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11:301.</a></li><li><a class="nounderline abstract_t">Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients. Transplantation 1994; 58:658.</a></li><li><a class="nounderline abstract_t">Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60:648.</a></li><li><a class="nounderline abstract_t">Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62:1744.</a></li><li><a class="nounderline abstract_t">Frei UA, Neumayer HH, Buchholz B, et al. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Transplantation 1998; 65:1455.</a></li><li><a class="nounderline abstract_t">Pescovitz MD, Barone G, Choc MG Jr, et al. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. Transplantation 1997; 63:778.</a></li><li><a class="nounderline abstract_t">Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant 2016; 16 Suppl 2:11.</a></li><li><a class="nounderline abstract_t">Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2015; :CD007746.</a></li><li><a class="nounderline abstract_t">Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34:296.</a></li><li><a class="nounderline abstract_t">Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64:1277.</a></li><li><a class="nounderline abstract_t">Lang P, Pardon A, Audard V. Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation 2005; 79:S47.</a></li><li><a class="nounderline abstract_t">Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18:1973.</a></li><li><a class="nounderline abstract_t">Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3:68.</a></li><li><a class="nounderline abstract_t">A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.</a></li><li><a class="nounderline abstract_t">Goldfarb-Rumyantzev AS, Smith L, Shihab FS, et al. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 2006; 1:563.</a></li><li><a class="nounderline abstract_t">Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.</a></li><li><a class="nounderline abstract_t">Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364:503.</a></li><li><a class="nounderline abstract_t">Burke GW, Ciancio G. Show me the money--immunosuppression in kidney transplantation. Lancet 2004; 364:481.</a></li><li><a class="nounderline abstract_t">Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015; 10:136.</a></li><li><a class="nounderline abstract_t">Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4:231.</a></li><li><a class="nounderline abstract_t">Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4:237.</a></li><li><a class="nounderline abstract_t">Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006; 66:103.</a></li><li><a class="nounderline abstract_t">Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 2006; 66:112.</a></li><li><a class="nounderline abstract_t">Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006; 82:1413.</a></li><li><a class="nounderline abstract_t">Sollinger HW, Sundberg AK, Leverson G, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010; 89:446.</a></li><li><a class="nounderline abstract_t">Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 2011; 91:470.</a></li><li><a class="nounderline abstract_t">Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int 2005; 18:1121.</a></li><li><a class="nounderline abstract_t">Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009; 9:2597.</a></li><li><a class="nounderline abstract_t">Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20:63.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4:2058.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5:2273.</a></li><li><a class="nounderline abstract_t">Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7:586.</a></li><li><a class="nounderline abstract_t">Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006; :CD004290.</a></li><li><a class="nounderline abstract_t">Lim WH, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 2014; 14:2106.</a></li><li><a class="nounderline abstract_t">Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014; 349:g6679.</a></li><li><a class="nounderline abstract_t">Pascual J, Berger SP, Witzke O, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 2018; 29:1979.</a></li><li><a class="nounderline abstract_t">Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377:837.</a></li><li><a class="nounderline abstract_t">Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233.</a></li><li><a class="nounderline abstract_t">Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21:1587.</a></li><li><a class="nounderline abstract_t">Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535.</a></li><li><a class="nounderline abstract_t">Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547.</a></li><li><a class="nounderline abstract_t">Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528.</a></li><li><a class="nounderline abstract_t">Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:66.</a></li><li><a class="nounderline abstract_t">Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12:630.</a></li><li><a class="nounderline abstract_t">Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210.</a></li><li><a class="nounderline abstract_t">Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13:2875.</a></li><li><a class="nounderline abstract_t">Charpentier B, Medina Pestana JO, Del C Rial M, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13:2884.</a></li><li><a class="nounderline abstract_t">Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med 2016; 374:333.</a></li><li><a class="nounderline abstract_t">Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6:430.</a></li><li><a class="nounderline abstract_t">Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014; :CD010699.</a></li><li><a class="nounderline abstract_t">Woodle ES, Kaufman DB, Shields AR, et al. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. Am J Transplant 2020; 20:1039.</a></li><li><a class="nounderline abstract_t">Florman S, Pestana JM, Rial M, et al. Final results from the BENEFIT-EXT trial: A 7-year follow-up of Belatacept treated patients. Am J Transplant 2015; 15(S3):1.</a></li><li><a class="nounderline abstract_t">de Graav GN, Baan CC, Clahsen-van Groningen MC, et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. Transplantation 2017; 101:2571.</a></li><li><a class="nounderline abstract_t">Kaufman DB, Woodle ES, Shields AR, et al. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial. Clin J Am Soc Nephrol 2021; 16:1387.</a></li><li><a class="nounderline abstract_t">Grinyó JM, Del Carmen Rial M, Alberu J, et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis 2017; 69:587.</a></li><li><a class="nounderline abstract_t">Darres A, Ulloa C, Brakemeier S, et al. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study. Transplantation 2018; 102:1545.</a></li><li><a class="nounderline abstract_t">Bertrand D, Chavarot N, Gatault P, et al. Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrol Dial Transplant 2020; 35:336.</a></li><li><a class="nounderline abstract_t">Chavarot N, Divard G, Scemla A, et al. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. Am J Transplant 2021; 21:2448.</a></li><li><a class="nounderline abstract_t">Budde K, Prashar R, Haller H, et al. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. J Am Soc Nephrol 2021; 32:3252.</a></li><li><a class="nounderline abstract_t">Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46:13.</a></li><li><a class="nounderline abstract_t">Kuypers DR. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transpl Int 2005; 18:140.</a></li><li><a class="nounderline abstract_t">Rupprecht K, Schmidt C, Raspé A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009; 49:1196.</a></li><li><a class="nounderline abstract_t">Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010; 49:2061.</a></li><li><a class="nounderline abstract_t">Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 2012; 52:1265.</a></li><li><a class="nounderline abstract_t">Knorr JP, Sjeime M, Braitman LE, et al. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation 2014; 97:518.</a></li><li><a class="nounderline abstract_t">Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc 2010; 42:4243.</a></li><li><a class="nounderline abstract_t">Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30:46.</a></li><li><a class="nounderline abstract_t">Gabardi S, Olyaei A. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. Ann Pharmacother 2012; 46:1054.</a></li><li><a class="nounderline abstract_t">Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant 2009; 9:1650.</a></li><li><a class="nounderline abstract_t">Kiberd BA, Wrobel M, Dandavino R, et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit 2011; 33:120.</a></li><li><a class="nounderline abstract_t">Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol 2015; 80:1086.</a></li><li><a class="nounderline abstract_t">Gregoor PJ, de Sévaux RG, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68:1603.</a></li><li><a class="nounderline abstract_t">Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14:706.</a></li><li><a class="nounderline abstract_t">van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17:871.</a></li><li><a class="nounderline abstract_t">Al Sagheer T, Enderby CY. Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients. Clin Transplant 2019; 33:e13727.</a></li></ol></div><div id="topicVersionRevision">Topic 7356 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808409" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Monozygotic transplantation: concerns and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11317972" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Renal homotransplantation in identical twins. 1955.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6996622" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal isotransplantation without immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270364" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Living related kidney transplantation between identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36032031" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095056" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157605" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094377" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reduced exposure to calcineurin inhibitors in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755536" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37778459" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28544101" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595191" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : OPTN/SRTR 2019 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33533901" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients: Long-term Outcomes of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27546100" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid avoidance or withdrawal for kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37650722" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104432" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Late steroid withdrawal and cardiovascular events in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048349" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33826598" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Panel-reactive Antibody and the Association of Early Steroid Withdrawal With Kidney Transplant Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10213717" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9275110" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112351" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829910" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741208" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11888584" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30588970" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003231" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177637" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal graft survival and calcineurin inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688516" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17217442" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840480" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278376" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113208" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715050" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279614" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27340950" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8824473" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178343" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8207699" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165192" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7940685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570970" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8990355" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26755262" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26633102" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430977" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371668" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699751" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term benefit of mycophenolate mofetil in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460145" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645033" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492713" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623181" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699260" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of maintenance immunosuppressive regimen in kidney transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752752" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302193" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302174" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Show me the money--immunosuppression in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490561" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunosuppressive drugs and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974944" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974945" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939066" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939067" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164710" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177347" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245794" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162098" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843035" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3291299" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575910" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095509" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229066" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625599" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088685" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422259" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29752413" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334736" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155978" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634298" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Five-year safety and efficacy of belatacept in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415897" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415898" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076381" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114656" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22300431" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21992533" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24047110" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24103072" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term exposure to belatacept in recipients of extended criteria donor kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26816011" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Belatacept and Long-Term Outcomes in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051752" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416857" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Belatacept for kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31680394" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Final results from the BENEFIT-EXT trial: A 7-year follow-up of Belatacept treated patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28403127" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34233921" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27889299" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29570163" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32030416" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Opportunistic infections after conversion to belatacept in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283406" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34706967" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201457" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15691265" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783713" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671023" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903891" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162246" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168674" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18223462" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22811345" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519820" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192310" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913040" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589962" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193823" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452491" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31587353" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
